4.6 Article

Rapid and Accurate Diagnosis of the Respiratory Disease Pertussis on a Point-of-Care Biochip

期刊

ECLINICALMEDICINE
卷 8, 期 -, 页码 72-77

出版社

ELSEVIER
DOI: 10.1016/j.eclinm.2019.02.008

关键词

Pertussis diagnosis; Point-of-care detection; Microfluidic biochip; Whooping cough; Loop-mediated isothermal amplification (LAMP)

资金

  1. National Institute of Allergy and Infectious Disease of the NIH [R21AI107415]
  2. Philadelphia Foundation
  3. Medical Center of the Americas Foundation
  4. U.S. NSF-PREM program [DMR 1205302, 1827745]
  5. National Institute of General Medical Sciences of the NIH [SC2GM105584]
  6. NIH RCMI Pilot grant
  7. NIH BUILDing Scholar Summer Sabbatical Award (NIGMS) [RL5GM118969, TL4GM118971, UL1GM11897]
  8. University of Texas at El Paso (UTEP)
  9. University of Texas System
  10. National Institutes on Minority Health and Health Disparities (NIMHD) [G12MD007592]

向作者/读者索取更多资源

Background: Pertussis is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis (B. pertussis). The infection is difficult to diagnose especially in underserved or resource-limited areas. We developed a low-cost and instrument-free diagnostic method for rapid and accurate detection of B. pertussis on a point-of-care (POC) testing device. Methods: We developed a paper/polymer hybrid microfluidic biochip integrated with loop-mediated isothermal amplification (LAMP) method for the rapid and accurate detection of B. pertussis. This microfluidic approach was validated by testing 100 de-identified remnant clinical nasopharyngeal swabs and aspirates, which were confirmed to be either positive or negative for B. pertussis by a validated real-time PCR assay at the Children's Hospital Los Angeles. Findings: The instrument-free detection results could be successfully read by the naked eye within 45 min with a limit of detection (LOD) of 5DNA copies perwell. Our optimized bacterial lysis protocol allowed the direct testing of clinical samples without any complicated sample processing/preparation (i.e. DNA extraction) or the use of any equipment (e.g. centrifuges). The validation of the microfluidic approach was accomplished by testing 100 clinical samples. High sensitivity (100%) and specificity (96%) with respect to real-time PCR were achieved. Interpretation: This microfluidic biochip shows great potential for point-of-care disease diagnosis in various venues including schools and physician's offices, especially in low-resource settings in developing nations. (C) 2019 Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据